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Diﬀerential expression of the interleukin 5 receptor a isoforms
in blood and tissue eosinophils of nasal polyp patients
Interleukin-5 (IL-5) plays a central role in an eosinophils
life span: it supports eosinophilopoiesis and eosinophil
diﬀerentiation, contributes to eosinophil migration, tissue
localization and function, and prevents eosinophil apop-
tosis (1, 2). Given the likely role of eosinophils in chronic
inﬂammatory diseases, many research focused at antag-
onizing the IL-5 function. It appears from recent studies
that, although this can easily be achieved in vitro (3, 4),
blocking IL-5 function in vivo is much more diﬃcult than
originally anticipated (5). In nasal polyposis we demon-
strated that a single intravenous injection of anti-IL-5
(mepolizumab) is eﬀective and reduces the size of nasal
polyps in 50% of the patients, and that nasal IL-5 levels
predict the response to anti-IL-5 treatment (6). Flood-
Page et al. observed a signiﬁcant diﬀerential eﬀect of IL-5
blockade on eosinophil counts in various body compart-
ments (7). After multiple dosing with mepolizumab, there
was a 100% median reduction in eosinophils in blood,
79% in bronchoalveolar lavage, but only a 52% in the
bone marrow and a 55% decrease in the bronchial
mucosa (7). The exact reason for a diﬀerent eﬀect of anti-
IL-5 in diﬀerent body compartments is unclear, but recent
data indicated varying IL-5 sensitivity and IL-5 receptor
expression at diﬀerent time points in the cells formation
and localization (8).
The interleukin-5 receptor (IL-5R) is a complex con-
sisting of two chains (9). The soluble (SOL) variant of the
IL-5Ra has antagonistic properties in vitro, whereas the
transmembrane (TM) IL-5Ra can bind with the bc-chain
leading to a high aﬃnity receptor complex. The bc-chain
does not bind IL-5 by itself but provides the major
determinants for signaling whereby IL-5 ligation results
in internalization and degradation of the bc-chain (10). It
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is suggested that eosinophils are able to control their
responsiveness to IL-5 by regulating the expression of the
IL-5Ra isoforms. However, this regulated expression may
change during eosinophil diﬀerentiation, maturation and
localization. On CD34+ progenitor cells, it has been
demonstrated that IL-5 induces a switch from predom-
inantly SOL isoform to TM-IL-5RamRNA expression at
the splicing level (11). In mature blood eosinophils, IL-5,
IL-3 and GM-CSF down-regulate IL-5Ra mRNA in a
dose dependent manner at the promoter level (12). Liu
et al. showed that IL-5 receptor expression on airway
eosinophils is down-modulated in vivo after inhaled
allergen challenge and that this may be due to cleavage
by membrane associated metalloproteinases (13, 14). In
addition, Gregory et al. have demonstrated that exposure
of blood eosinophils to IL-3, IL-5, or granulocyte-
macrophage colony-stimulating factor in vitro leads to
sustained down-regulation of surface IL-5Ra expression
and reduced responsiveness to IL-5 (15). It seems that
IL-5R expression is regulated by diﬀerent mechanisms
ranging from alternative splicing of the IL-5Ra isoforms
to cleavage by membrane associated metalloproteinases.
We hypothesize that the expression of the IL-5Ra
isoforms may be diﬀerent depending on eosinophil
activation state, maturation and localization. Therefore,
we studied SOL-IL-5Ra and TM-IL-5Ra expression in
blood and in nasal tissue from control subjects and nasal
polyp (NP) patients. At the transcript level IL-5Ra
isoform expression was determined by a quantitative
real-time PCR. On the protein level SOL- IL-5Ra
concentrations were measured by ELISA (16), whereas
TM-IL-5Ra receptor expression on tissue and blood
eosinophils was determined by ﬂow-cytometry. The
eosinophil activation was determined by CD69 expression
and/or ECP release. Furthermore, we aimed to investi-
gate whether in vitro stimulation of peripheral blood
eosinophils with IL-5 could regulate the IL-5Ra isoform
expression similar to the expression found in tissue
eosinophils and its relation to membrane type-1 matrix
metalloproteinases.
Material and methods
Patients
Thirty-four subjects with Chronic rhinosinusitis with NP and 16
controls were recruited at the Departments of Otorhinolaryngology
at the Ghent University Hospital, Belgium and the Karolinska
Hospital in Stockholm, Sweden (Table 1). Peripheral blood and NP
samples were collected in 34 NP subjects (mean age 51.4 years,
range 22–79 years; 12 females/22 males) during routine endoscopic
sinus surgery and immediately processed for ELISA and PCR
measurements, whereas ﬂow-cytometry was performed on blood
and tissue samples of 11 NP subjects. Nasal polyps were diagnosed
based on history, clinical examination, nasal endoscopy and sinus
CT-scan. A history of asthma was reported in 17 NP patients, with
seven subjects additionally demonstrating a history of aspirin
intolerance. Subjects with concurrent asthma were allowed on no
more than 1000 mcg/day BDP or the equivalent, whereas nasal
glucorticosteroids were only allowed up to one week before surgery.
Patients treated with oral corticoids within the last four weeks prior
to surgery were excluded.
Blood and nasal tissue (inferior turbinates) from healthy con-
trols were obtained during routine corrective nasal surgery. All
controls (mean age 34.5 years, range 18–71 years; seven females/
nine males) were skin prick test negative, in generally good
health, and none had a history of nasal or sinus disease, allergic
disease (asthma, rhinitis or dermatitis), upper respiratory tract
infection in the previous month, use of any intranasal medica-
tions, decongestants, antihistamines or oral steroids. The ethical
committees of both universities approved this study and a written
informed consent was obtained from all subjects before inclusion
in the study.
Preparation of nasal tissue
Removed polyps were transferred to +4C HEPES (10 mM)-
buﬀered RPMI 1640 medium (Gibco, Paisley, UK). The polyp tis-
sue was either homogenized or prepared to single cell suspension.
To obtain tissue homogenates, nasal tissue specimens were weighed,
and 1 ml of 0.9% NaCl solution was added for every 0.1 g of tissue
and then homogenized with a mechanical homogenizer (B. Braun,
Melsungen, Germany) as described previously (17).
For single cell suspensions, the tissue was cut into small pieces,
passed through a ﬁne wire mesh by a syringe stamper and rinsed
with RPMI. The cell suspension was centrifuged at 200 g for
<1 min at +4C and remaining tissue elements were sedimented.
The cell supernatant was further centrifuged at 300 g for 12 min at
+4C. The cells were separated, one part was lysed and stored at
)80C until RNA puriﬁcation. The other part was resuspended in
5 ml PBS and used for FACS analysis.
Preparation of blood and serum
Peripheral blood was collected in tubes containing EDTA (Vacu-
tainer, 5 ml, with 50 ll of 21% EDTA) (Terumo, Leuven, Belgium).
Leukocytes were isolated by hemolysing 150 ll portions of blood in
3 ml +4C isotonic NH4Cl-EDTA lysing solution (154 mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2) for 5 min at
+15ºC. Cell suspensions were then centrifuged at 300 g for 6 min at
+4ºC and washed in PBS. The cells were used for RNA prepara-
tions and FACS analysis. Serum was collected in tubes with no
additives, was allowed to coagulate for 30 min and centrifuged at
1500 g for 15 min at +4C.
Preparation of purified peripheral blood eosinophils
Peripheral blood eosinophils from healthy blood donors (age
18–64 years) were puriﬁed by the magnetic cell separation system
Table 1. Patient characteristics
Controls Nasal polyps
Number (n) 16 34
Age (years) 34.5 (18–71) 51.4 (22–79)
Male : female 9 : 7 22 : 12
Allergy (SPT+) 0% (0/16) 44% (15/34)
Asthma 0% 50% (17/34)
Aspirin intolerance 0% 21% (7/34)
Recurrent NP after surgery 0% 32% (11/34)
Gevaert et al.
 2009 The Authors
726 Journal compilation  2009 Blackwell Munksgaard Allergy 2009: 64: 725–732
MidiMacs (Miltenyi, Biotec, Bergisch Gladbach, Germany) (18).
Brieﬂy, blood was layered onto Percoll solution (Pharmacia-
Upjohn, Uppsala, Sweden) and centrifuged (30 min, 1000 g,
20C). The mononuclear cell layer was removed and the
remaining cell suspension was hemolysed in isotonic lysing solu-
tion (154 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2).
Eosinophils and neutrophils were washed in PBS and anti-CD16
magnetic beads were added for 20 min at +4C. The eosinophils
were obtained by negative selection using a separation column in
a magnetic ﬁeld where magnetically labeled cells (CD16+ neu-
trophils) were trapped and unlabelled cells (eosinophils) were
collected.
In vitro incubation of purified eosinophils with recombinant human
IL-5
Puriﬁed eosinophils (1.0 · 106/ml) were incubated with
recombinant human (rh) IL-5 (10 ng/ml) (Immunokontact,
Frankfurt, Germany) diluted in HEPES (10 mM)-buﬀered RPMI
1640 medium (Gibco, Paisley, UK) supplemented with 10% heat-
inactivated fetal calf serum (RPMI). As control, eosinophils were
incubated in RPMI alone. The cell suspensions were incubated in
24-well plates for 2 h or 24 h at +37C in 5% CO2. Supernatants
were collected and stored at )30C until ELISA measurements. The
cells were washed twice in PBS (300 g for 5 min at +4C) and used
for FACS.
Immunofluorescence staining of eosinophils and flow-cytometry
Polyp tissue cells (0.5–1.0 · 106), isolated blood leukocytes or
puriﬁed eosinophils (0.1 · 106) were incubated with non-conjugated
mAb to IL-5Ra (10 lg/ml, Clone: a16, non-neutralizing). Second-
ary immunostaining was performed with ﬂuoroscein isothiocyanate
(FITC)-conjugated Rabbit Anti Mouse immunoglobulin, F(ab¢)2
(50 lg/ml, Code: F313) (DAKO A/S). Polyp tissue cells and blood
leukocytes were double stained with phycoerythrin (PE)-conjugated
mAb to CD16 (Immunotech) or stained with FITC-conjugated
mAb to CD69 (5 lg/ml, Clone: L78) (Becton Dickinson, Meylan-
Cedex, France) together with mAb to CD16 (Immunotech). Cells
and antibodies were incubated for 30 min at +4C, and then
washed in PBS. Non-speciﬁc binding was determined with isotype-
matched control antibodies in corresponding concentrations. Cells
were ﬁnally diluted in 0.5 ml PBS and a minimum of 1000 eosin-
ophils was analyzed in an EPICS XL-MCL (Beckman Coulter Inc.,
Fullerton, CA, USA) ﬂow-cytometer. Polyp tissue and peripheral
blood eosinophils were detected and analyzed as a separate CD16
negative population by using depolarized light (19). The ﬂow-
cytometer was calibrated daily with Flow Check and Flow Set
(Beckman Coulter).
Measurement of IL-5 and SOL IL-5 Ra protein concentrations
A SOL-IL-5Ra speciﬁc sandwich ELISA was developed by com-
bining two monoclonal antibodies (Innogenetics, Gent, Belgium).
A detailed description and characterization of this ELISA was pre-
viously published (16). Serum, tissue homogenates and eosinophil
supernatants were assayed by a research ELISA for SOL-IL-5Ra
(Innogenetics) and IL-5 (R&D Systems, Minneapolis, MN, USA).
SOL and TM IL-5 Ra real-time PCR
RNA was isolated from snap frozen blood leukocytes and nasal
tissue cells of 16 controls and 34 NP patients using the Rneasy Kit
(Qiagen, Hilden, Germany), whereas RNA from eosinophil cell
pellets was extracted using the TriReagent method (Sigma, Bornem,
Belgium). Total RNA was quantiﬁed using RiboGreen Kit
(Molecular Probes, Merelbeke, Belgium) and 0.5 lg was reverse
transcribed using Superscript II Reverse Transcriptase (Invitrogen,
Merelbeke, Belgium), oligo dT and random hexamers (Amersham
Pharmacia Biotech, Buckinghamshire, UK) according to the man-
ufactures protocol. cDNA equivalent to 25 ng total RNA was used
to perform the Real Time PCR. The Real Time ampliﬁcations were
performed using the 1X SYBR Green I Mastermix (Qiagen) and a
set of primers including a common forward primer and speciﬁc
reverse primers for SOL hIL-5Ra and TM hIL-5Ra isoforms as
previously published (20). Two plasmids containing the cDNA
sequences for the soluble or membrane-anchored encoding tran-
scripts of hIL-5Ra were used to prepare the template for the stan-
dards (provided by Prof. Dr Jan Tavernier). MMP-14 RT-PCR was
done with Assay-on-Demand Gene Expression products (Applied
Biosystems, Foster City, CA, USA). PCR was performed in a 25 ll
reaction mixture composed of cDNA (equivalent to 25 ng total
RNA), primers and FAM-labeled probes and TaqMan Universal
PCR Master mix (Applied Biosystems). All the PCRs were per-
formed in a 5700 SDS Thermal Cycler (Applied Biosystems). Each
sample was tested in duplicate. The quantity of each amplicon was
calculated from the values of each standard curve and normalized
by the quantities obtained for b-actin transcripts (21).
Statistical analysis
Data are expressed as median and interquartile range (IQR). When
comparisons were made between groups, signiﬁcant between-group
variability was ﬁrst established using Kruskal–Wallis test. The
Mann–Whitney U-test was then used for between-group (unpaired)
comparison. Diﬀerences between the paired data were calculated by
using the Wilcoxon test. Spearman rank correlation coeﬃcient (r)
was used to assess relationships between parameters.
Results
SOL-IL-5Ra and TM-IL-5Ra protein expression in blood and tissue
We found increased median (IQR) concentrations of
SOL-IL-5Ra in serum from 17 NP patients with con-
comitant asthma (778 pg/ml; 501–1191) compared to 16
controls (285 pg/ml; 226–465; P = 0.009) and 17 NP
patients without asthma (328 pg/ml; 272–448;
P < 0.001). Whereas SOL-IL-5Ra could be measured
in all serum samples, IL-5 protein concentrations were
only measurable in four subjects (all with concomitant
asthma). In controls the median percentage of blood
eosinophils was 1.2% (0.5–2.5), whereas increased per-
centages were found in NP (3.6%; 2.5–5.9; P = 0.02) and
NP with asthma (9.7%; 6.9–19.5; P < 0.001) and with
a signiﬁcant diﬀerence between the NP groups
(P < 0.001).
In supernatants prepared from nasal tissue homogen-
ates median (IQR) concentrations of SOL-IL-5Ra were
signiﬁcantly higher in NP (1504 pg/ml; 1037–3757;
P = 0.04) and NP with concomitant asthma (21069 pg/
ml; 13 177–29 784; P < 0.001) compared to control
nasal tissue (919 pg/ml; 735–1416). Whereas IL-5 was
not detectable in control nasal tissue, increased IL-5
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concentrations were found in NP tissue of patients
without (56 pg/ml; 43–197; P = 0.03) and with concom-
itant asthma (244 pg/ml; 107–367; P = 0.002). Within
the NP group, there was a signiﬁcant further increase of
SOL-IL-5Ra (P < 0.001) and IL-5 (P = 0.01) in
patients with concomitant asthma compared to patients
without asthma. Increased eosinophil percentages were
found in NP tissue with (11.3%; 8.1–25.7; P < 0.001)
and without concomitant asthma (2.4%; 1.2–5.8;
P = 0.006) compared to control tissue (0.2%; 0.1–0.5).
Moreover, in NP tissue, SOL-IL-5Ra signiﬁcantly
correlated with concentrations of IL-5 (r = 0.500;
P = 0.02), and percentage of eosinophils (r = 0.589;
P = 0.003).
When peripheral blood and polyp tissue cells were
analyzed by ﬂow-cytometry the proportion of TM-IL-
5Ra positive eosinophils was signiﬁcantly (P = 0.003)
lower in polyp tissue eosinophils, 6.1% (1.3–10.4) when
compared to peripheral blood eosinophils, 72.6% (60.6–
86.4) (n = 11). The proportion of CD69 positive eosin-
ophils was signiﬁcantly (P = 0.018) up regulated on
polyp tissue eosinophils, 63.9% (63.0–78.4), as compared
to peripheral blood eosinophils, 2.7% (1.9–3.6) (Fig. 1).
No relevant correlations were found for CD69 and
TM-IL-5Ra expression on blood and tissue eosinophils.
The percentage of TM-IL-5Ra positive eosinophils
ranges in peripheral blood from 70.4% (41.5–86.4) to
72.6% (69.0–82.4), whereas in tissue from 6.9% (1.3–
10.4) to 6.1% (2.2–12.7) in NP without asthma (n = 6)
and with asthma (n = 5). The proportion of CD69
positive eosinophils ranges in peripheral blood from 2.2%
(1.3–2.74) to 3.0% (2.5–3.7), whereas in tissue from
66.9% (63.0–78.4) to 63.9% (60.3–70.6) in NP without
asthma (n = 6) and with asthma (n = 5) any signiﬁcance
between the groups. There was no signiﬁcant diﬀerences
in expression of TM-IL-5Ra or CD69 between NP with
or without asthma.
SOL-IL-5Ra and TM-IL-5Ra mRNA expression in blood and tissue
Analysis of peripheral blood and nasal tissue samples
with quantitative real-time PCR revealed that relative
amounts of SOL-IL-5Ra and TM-IL-5Ra isoforms
(copies of mRNA/ll), were signiﬁcantly higher in samples
of patients with NP compared to controls. Within the NP
group, SOL-IL-5Ra and TM-IL-5Ra mRNA levels were
increased in peripheral blood of patients with concomi-
tant asthma compared to patients without asthma
(Fig. 2A). In NP tissue of patients with asthma the
SOL-IL-5Ra mRNA was signiﬁcantly increased whereas
the TM-IL-5Ra mRNA was signiﬁcantly decreased when
compared to NP patients without asthma (Fig. 2B). In
peripheral blood samples of NP patients, relative
amounts of SOL-IL-5Ra and TM-IL-5Ra mRNA were
signiﬁcantly correlated to eosinophil percentages
(Fig. 2A). In polyp tissue, protein concentrations of
IL-5, SOL-IL-5Ra, and eosinophil percentages correlated
positively to SOL-IL-5Ra, but inversely to TM-IL-5Ra
mRNA expression (Fig. 2B).
Analysis of SOL-IL-5Ra and TM-IL-5Ra protein and mNRA
expression in subgroups
Although the presence of asthma seems to be the
strongest diﬀerentiator in SOL-IL-5Ra and TM-IL-5Ra
protein and mNRA expression, other factors play a role.
It needs to be mentioned that recurrent nasal polyposis,
asthma and aspirin intolerance are strongly linked (not
atopy). Within the NP group, atopy based on positive
skinprick tests was only associated with increased SOL-
IL-5Ra protein expression. Recurrent nasal polyposis
and aspirin intolerance were associated with signiﬁcantly
lower TM-IL-5Ra protein and mRNA expression.
SOL-IL-5Ra and TM-IL-5Ra protein expression after in vitro
stimulation with rh IL-5
Puriﬁed eosinophils from seven healthy blood donors
were incubated with rh IL-5 for 2 h and 24 h. Flow
cytometric analysis showed that rh IL-5 induced a
signiﬁcant (P = 0.018 for all) down-regulation in the
proportion of TM-IL-5Ra positive eosinophils at 2 h,
37.5% (27.4–61.8) and 24 h, 13.9% (8.8–22.0) as
compared to the RPMI controls, 78.3% (68.1–86.0)
and 55.0% (46.9–62.3), respectively (Fig. 3A). The
SOL-IL-5Ra concentrations in the supernatants were
signiﬁcantly higher after incubation with rh IL-5
compared to RPMI controls at 2 h (P = 0.002) and
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Figure 1. TM-IL-5Ra and CD-69 (eosinophil activation mar-
ker) expression was evaluated by FACS analysis in blood and in
tissue of 12 NP patients. The results are presented as the pro-
portion of TM-IL-5Ra (ﬁlled symbols) and CD-69 (open sym-
bols) positive eosinophils. Statistical analyses were performed
using the Wilcoxon test.
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24 h (P = 0.03) (Fig. 3B). SOL-IL-5Ra and TM-IL-5Ra
protein expression correlated negatively at 24 h
(r = )0.612; P = 0.03).
SOL-IL-5Ra and TM-IL-5Ra mRNA expression after in vitro
stimulation with rh IL-5
Stimulation of blood eosinophils with rh IL-5 resulted in
a signiﬁcant decrease in TM-IL-5Ra mRNA expression
after 2 and 24 h compared to baseline, which is at both
time points signiﬁcantly lower when compared to the
RPMI controls (Fig. 3C). SOL-IL-5Ra mRNA expres-
sion decreased signiﬁcantly after 2 and 24 h, without
diﬀerence between rh IL-5 incubation and RPMI controls
(Fig. 3D). There was no diﬀerence in relative MMP-14
mRNA expression (b-actin corrected) between diﬀerent
time points or between stimulation with rh IL-5 and
RPMI controls. MMP-14 expression was positively
correlated with SOL-IL-5Ra (protein and mRNA)
(r = 0.354; P > 0.05 and r = 0.786; P = 0.005) and
TM-IL-5Ra mRNA expression(r = 0.638; P = 0.02),
whereas a negative correlation was shown with
TM-IL-5Ra surface expression (r = )0.750; P = 0.007).
Discussion
Our results demonstrate diﬀerential expression of
IL-5Ra isoforms in blood and tissue eosinophils. In
blood, SOL-IL-5Ra and TM-IL-5Ra mRNA and pro-
tein expression is up-regulated in NP vs controls and
correlated to eosinophil percentages, whereas in polyp
tissue TM-IL-5Ra levels showed an inverse relation
to eosinophilia and SOL-IL-5Ra expression. Blood
eosinophils express high levels of surface-anchored
TM-IL-5Ra and are not activated as judged by a low
CD-69 expression. In contrast, tissue eosinophils are
activated and demonstrate a low level of surface
receptors to IL-5. Recently, it was demonstrated that
following airway antigen challenge of atopic subjects,
BAL ﬂuid eosinophils showed a markedly reduced TM-
IL-5Ra and bc-chain mRNA and did not release EDN
when exposed ex vivo to IL-5 compared with circulating
eosinophils (14). Julius et al. (22) demonstrated that
TM-IL-5Ra on blood and BAL eosinophils was
decreased after segmental allergen provocation in 12
atopic asthmatics, whereas CD-69 (activation marker)
increased. Interestingly, the net decrease in IL-5Ra
A B
Figure 2. Relative amounts of SOL-IL-5Ra and TM-IL-5Ra/b-actin (copies mRNA/ll) were determined by a isoform speciﬁc real-
time PCR in peripheral blood A; and in nasal tissue B; of 16 controls (C), 17 nasal polyps (NP) and 17 nasal polyp patients with
concomitant asthma (NP+Asth). The Box-and-whisker plot represents the median, the lower to upper quartile, and the minimum to
the maximum value, excluding far out values. Statistical analyses were performed using the Mann–Whitney U-test (ns = not
signiﬁcant). Spearman rank correlation coeﬃcient (r) was used to assess the relationships between the parameters.
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expression occurred in the presence of signiﬁcantly
elevated IL-5 concentrations in BAL ﬂuid (22). Simi-
larly, the decreased expression of TM-IL-5Ra on tissue
eosinophils from nasal polyps might prevent eosinophil
activation by IL-5. This insights are especially important
in order to understand the clinical trials with anti-IL-5 in
humans. We recently showed that nasal IL-5 levels
determined the response to anti-IL-5 treatment in
patients with nasal polyposis (6). Only in those patients
with highly increased nasal IL-5 levels a signiﬁcant
decrease in polyp volume was obtained up to four weeks
after one single injection with anti-IL-5. Probably only
highly increased local IL-5 levels can overcome the low
TM-IL-5Ra expression on tissue eosinophils. Nasal
polyposis is frequently associated with asthma and
particularly those patients have the highest levels of
IL-5 and eosinophil counts in the NP tissues (17, 23). In
line with this we now demonstrate that the SOL-IL-5Ra
expression is increased whereas the TM-IL-5Ra mRNA
expression is decreased in NP tissue of patients with
asthma compared to those without asthma. Further-
more, TM-IL-5Ra mRNA is inversely correlated to
protein levels of IL-5, SOL-IL-5Ra and the proportion
of eosinophils. This suggests TM-IL-5Ra mRNA tissue
expression is down-regulated independently of eosino-
phil counts and this further supports the ﬁnding that
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Figure 3. Puriﬁed eosinophils from seven healthy blood donors were incubated with 10 ng/ml rh IL-5 for 2 h and 24 h (RPMI+IL-5;
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tissue eosinophils have a low IL-5Ra surface expression.
Hence, in tissue with the highest levels of IL-5 and
eosinophils, a regulatory mechanism must operate to
control the ongoing eosinophilic inﬂammation by up-
regulation of SOL-IL-5Ra and down-regulation of
TM-IL-5Ra. Taken together, our results suggest that
the expression of the IL-5Ra isoforms diﬀers according
to the eosinophil activation state, maturation and
localization in the body.
Hellman et al. demonstrated that surface TM-IL-5Ra
was strongly down-regulated by recombinant IL-5,
intermediately with both IL-5 and GM-CSF, and
weakly with only GM-CSF, suggesting that GM-CSF
binding partially inhibits the surface IL-5 receptor to be
down-modulated (24). In the present study we show
that freshly isolated mature human blood eosinophils
express more SOL-IL-5Ra than TM-IL-5Ra mRNA
expression. In vitro exposure of mature human blood
eosinophils with rh IL-5 for 2 h and 24 h induces an
extensive down-regulation of IL-5Ra TM protein and
mRNA, whereas SOL-IL-5Ra was only signiﬁcantly
up-regulated at the protein level but not on the
transcript level. The discrepancy between the mRNA
and the protein level point to the fact that SOL-IL-5Ra
expression is mainly dependent of proteolytic cleavage
of the receptor rather than on regulation the transcript
level. Liu et al. (13) demonstrated that the down-
modulation of TM-IL-5Ra from the cell surface and
the increased release of SOL-IL-5Ra into culture
supernatant ﬂuid were partially inhibited by the
MMP-speciﬁc inhibitor BB-94 (13). These data suggest
that exposure of peripheral blood eosinophils to IL-5
results in a rapid, sustained loss of TM-IL-5Ra, that is,
at least in part, dependent on MMP activity. In line
with this we found a signiﬁcant inverse correlation
between MMP-14 and IL-5Ra surface expression,
which suggests a role in proteolytic cleavage of the
receptor. Taken all observations into account we
suggest that an IL-5 driven inﬂammation generates an
eosinophil tissue phenotype that is characterized by a
low TM but high SOL-IL-5Ra expression and that this
process is partially the result of proteolytic receptor
modulation and down-regulation of TM-IL-5Ra gene
transcription.
Conclusions
This report demonstrates diﬀerential expression of SOL-
IL-5Ra and TM-IL-5Ra in blood and tissue eosinophils.
Interestingly, in polyp tissue SOL-IL-5Ra expression is
increased and correlated to disease severity and eosin-
ophil percentages, whereas TM-IL-5Ra levels decreased
and were inversely correlated to eosinophils and SOL-
IL-5Ra expression. In vitro exposure of blood eosin-
ophils to IL-5 reduces the expression of TM-IL-5Ra,
but induces SOL-IL-5Ra protein release. SOL-IL-5Ra
protein has antagonistic properties in vitro, however
endogenous concentrations might be insuﬃcient to block
IL-5 activity. The expression of the IL-5Ra isoforms
diﬀers according to the eosinophil activation state,
maturation and localization in the body and may
therefore be involved in the ﬁne-tuning of the eosinophil
homeostasis.
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